Yuvraj Kumbkarni, MD
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1720076177
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,865 of the $188,506 with a category attached, or 67.8%. 60 manufacturers reported payments, led by Corcept Therapeutics at 24.6% of the total. 2025 is the largest year on record at $51,172, 3.4 times the $14,896 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,781 payments — averaging $105.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$46K
- Lilly USA, LLC$44K
- Boehringer Ingelheim$28K
- Sanofi-aventis U.S. LLC$15K
- Xeris Pharmaceuticals, Inc.$11K
- Intuity Medical Inc$8K
- plus $36K from 54 others
What the payments were for
- Consulting fees$10,3285%
- Speaking & faculty fees$127,86568%
- Travel & lodging$8,9215%
- Food & beverage$40,93222%
- Education$2320%
- Gifts$1190%
- Other$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$61,616
- Korlym$44,046
- GVOKE HYPOPEN$9,485
- Pogo Automatic Blood Glucose Monitoring System$7,487
- FARXIGA$4,788
- Tirosint$3,234
- MINIMED 770G$1,431
- CeQur Simplicity$484
- RYBELSUS$467
- TZIELD$390
- TEPEZZA$374
- EVENITY$346
- MINIMED 780G$262
- MYCAPSSA$247
- Kerendia$246
- GVOKE PFS$237
- Repatha$234
- EVERSENSE E3 SMART TRANSMITTER KIT$179
- Reveal LINQ$169
- RECORLEV$130
How this compares
$188,506 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $352,630 |
| JardianceEmpagliflozin | 167 | $194,406 |
| MounjaroTirzepatide | 121 | $169,099 |
| TrulicityDulaglutide | 90 | $121,209 |
| RybelsusSemaglutide | 68 | $114,327 |
| FarxigaDapagliflozin Propanediol | 69 | $70,032 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 58 | $58,888 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $52,275 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $51,103 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $46,951 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $45,195 |
| ProliaDenosumab | 25 | $43,237 |
| Humulin R U-500Insulin Regular, Human | 22 | $40,615 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $32,354 |
| Novolog FlexpenInsulin Aspart | 120 | $29,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $5,247 | $488,653340 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $44,304 | $297,920235 claims |
| Boehringer IngelheimJardiance, Tradjenta | $28,273 | $217,460187 claims |
| AstraZenecaFarxiga | $6,540 | $70,03269 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14,617 | $45,19543 claims |
| AmgenProlia | $2,506 | $43,23725 claims |
| AbbVieSynthroid, Armour Thyroid | $1,455 | $27,987269 claims |
| MerckJanuvia | $373 | $14,83814 claims |
| BayerKerendia | $1,402 | $7,76212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $308 | $4,300479 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Tampa
- Manuel Sainz de la PenaTampa$247K
- Andrew HenryTampa$173K
- Bryan McIverTampa$66K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.